JP2023537229A5 - - Google Patents

Info

Publication number
JP2023537229A5
JP2023537229A5 JP2023503508A JP2023503508A JP2023537229A5 JP 2023537229 A5 JP2023537229 A5 JP 2023537229A5 JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023537229 A5 JP2023537229 A5 JP 2023537229A5
Authority
JP
Japan
Prior art keywords
patient
enhancement
pharmaceutical composition
innate immunity
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537229A (ja
Filing date
Publication date
Priority claimed from PCT/IN2021/050325 external-priority patent/WO2021199078A2/en
Application filed filed Critical
Priority claimed from PCT/IN2021/050699 external-priority patent/WO2022018754A1/en
Publication of JP2023537229A publication Critical patent/JP2023537229A/ja
Publication of JP2023537229A5 publication Critical patent/JP2023537229A5/ja
Pending legal-status Critical Current

Links

JP2023503508A 2020-07-18 2021-07-19 ＳＡＲＳ－ＣｏＶ－２タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびＣＯＶＩＤ－１９を処置するための製剤 Pending JP2023537229A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN202021030633 2020-07-18
IN202021030633 2020-07-18
IN202021054151 2020-12-12
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.
INPCT/IN2021/050325 2021-03-30
PCT/IN2021/050699 WO2022018754A1 (en) 2020-07-18 2021-07-19 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (2)

Publication Number Publication Date
JP2023537229A JP2023537229A (ja) 2023-08-31
JP2023537229A5 true JP2023537229A5 (https=) 2024-07-26

Family

ID=79728594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503508A Pending JP2023537229A (ja) 2020-07-18 2021-07-19 ＳＡＲＳ－ＣｏＶ－２タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびＣＯＶＩＤ－１９を処置するための製剤

Country Status (7)

Country Link
US (1) US20240024337A1 (https=)
EP (1) EP4181917A4 (https=)
JP (1) JP2023537229A (https=)
AU (1) AU2021313476A1 (https=)
CA (2) CA3179022A1 (https=)
IL (1) IL300014A (https=)
WO (1) WO2022018754A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
CA3255538A1 (en) * 2022-04-07 2023-10-12 Shreema DR. MERCHANT METHOD FOR USING CANNABIDIOL IN THE PREVENTION AND TREATMENT OF INTERFERON-SENSITIVE CONDITIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520684A (ja) * 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
WO2021209998A1 (en) * 2020-04-14 2021-10-21 Molad Ami Composition for the treatment of respiratory symptoms and methods thereof
US20230181484A1 (en) * 2020-05-11 2023-06-15 Add Advanced Drug Delivery Technologies Ltd. Uses and Formulations of Cannabinoids
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Similar Documents

Publication Publication Date Title
JP2023537229A5 (https=)
Yuan et al. Microbiota in viral infection and disease in humans and farm animals
JP2023528561A5 (https=)
JP2017514911A5 (https=)
Berry Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System.
Xiao et al. Autophagy and viral infection
LT5079B (lt) Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai
Wang et al. Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation
Gao et al. Induction of SOCS expression by EV71 infection promotes EV71 replication
CN116251114A (zh) 龙胆苦苷在制备防控病毒或细菌感染的药物中的应用
JP2003528925A5 (https=)
Dianzani et al. Nonspecific defenses
KR20230012469A (ko) 바이러스 감염의 발생을 치료, 예방 또는 제한하기 위한 방법 및 조성물
Denholm et al. SARS-CoV-2-induced senescence as a potential therapeutic target
EP2683369B1 (en) Multiantivirus compound, composition and method for treatment of virus diseases
EP4504686A2 (en) A method of use for cannabidiol in the prevention and treatment of interferon-responsive conditions
Stebbing et al. Kaposi's sarcoma—an update
Yuliia MEDICAL SCIENCES
Haq TYPE I INTERFERON: ANTIVIRAL IS NEED OF THE TIME FOR COVID-19
US20230277650A1 (en) Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv)
Abbaszadeh et al. Bacteriophages: A possible choice for treatment of viral respiratory infections and COVID-19
Brandão et al. Prolonged survival of rabid mice after treatment with Poly-ICLC Hiltonol®
Mtewa et al. SARS-CoV-2 vaccine development
Kovesdi et al. Natural and artificial viral interference in viral diseases
JPWO2025105377A5 (https=)